패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Summit Therapeutics Inc. 17 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Gary Waanders	Bryan Garnier & Co
Timothy Chiang	BTIG
Arlinda Lee	Canaccord Genuity

Summit Therapeutics 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Recent updates

Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Summit Therapeutics Inc. to Report Q3, 2024 Results on Oct 30, 2024

Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market

Summit Therapeutics Inc. Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Summit Therapeutics Inc. announced that it has received $234.945 million in funding

Summit Therapeutics Inc. Announces Data Relating to the HARMONi-2 Trial

Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)

Summit Therapeutics May Have Further Upside From Here

Summit Therapeutics Inc. to Report Q2, 2024 Results on Aug 06, 2024

Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 3000E Index

Summit Therapeutics Inc. Appoints Jeff Huber to Its Board of Directors

Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP

Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP

Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival

Summit Therapeutics Stock: Plunging Despite A Win?

Summit Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $90 million.

New major risk - Share price stability

Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer

Summit Therapeutics Inc., Annual General Meeting, Jun 14, 2024

Summit Therapeutics Inc. to Report Q1, 2024 Results on May 01, 2024

Less than half of directors are independent

Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors

Summit Therapeutics Inc. Appoints Bhaskar Anand as Chief Accounting Officer, Head of Finance, to Serve as Its Principal Accounting Officer

Co-CEO, President & Director recently bought US$411k worth of stock

Summit Therapeutics Inc. Announces Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Summit Therapeutics Inc. Announces That Data for Its Novel, Potential First-In-Class Investigational Bispecific Antibody, Ivonescimab, Will Be Presented At the 2024 European Lung Cancer Congress (Elcc 2024) in Prague, Czech Republic

New minor risk - Financial position

Summit Therapeutics Inc. to Report Q4, 2023 Results on Feb 20, 2024

Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress

Summit Therapeutics Announces Updated Phase II Data for Ivonescimab At 42Nd Annual J.P. Morgan Healthcare Conference

Co-CEO, President & Director exercised options to buy US$2.1m worth of stock.

Laura Chow Joins Summit Therapeutics Inc. as Senior Vice President of Clinical Development

Summit Therapeutics Inc. to Report Q3, 2023 Results on Nov 07, 2023

Lead Independent Director recently bought US$5.0m worth of stock

Summit Therapeutics Inc. Announces Executive Changes

First half 2023 earnings released: US$1.03 loss per share (vs US$0.38 loss in 1H 2022)

Summit Therapeutics Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Share price stability

First quarter 2023 earnings released: US$1.43 loss per share (vs US$0.22 loss in 1Q 2022)

Summit Therapeutics Announces First Patient Treated in Phase III Harmoni Clinical Trial Evaluating Ivonescimab (SMT112)

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (Smt112)

Summit Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.41 loss per share (vs US$0.96 loss in FY 2021)

Summit Therapeutics Inc. Appoints Yu (Michelle) Xia as Member of the Board

Summit Therapeutics Inc. Appoints Alessandra Cesano to Its Board of Directors

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.20 loss in 3Q 2021)

Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole

Summit Therapeutics Inc. Announces Executive Changes

Summit Therapeutics slips on plans to terminate study for lead candidate

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.27 loss in 2Q 2021)

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Summit Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $99.91 million.

Summit Therapeutics Appoints Maky Zanganeh as Co-CEO

Summit Therapeutics Provides Update on Ridinilazole

Summit to explore additional trial for its bacteria-induced colon infection drug

Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 2000 Growth Index

Summit Therapeutics Inc. Appoints Ankur Dhingra as Chief Financial Officer

First quarter 2022 earnings released: US$0.22 loss per share (vs US$0.21 loss in 1Q 2021)

Summit Therapeutics Inc., Annual General Meeting, Jun 15, 2022

Less than half of directors are independent

Less than half of directors are independent

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Summit Therapeutics Inc. Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection

Summit Therapeutics Inc. Provides Update on Ri-CoDIFy Trials

Summit Therapeutics Presents Research Data from Phase II Studies, Including Evidence Validating Microbiome Preservation, for Its Investigational Drug Ridinilazole

Summit Therapeutics to Present Research Updates At the 31St Annual ECCMID Conference, Including A Top-Rated ePoster

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Summit Therapeutics to join Russell 3000 Index

Summit Therapeutics Inc. Announces Selected A New Preclinical Candidate, SMT026738

Summit Therapeutics Inc. Elects Dr. Michael Wang as Member of the Board